EVOLUTION Trial
Device: iVolution
Number of patients: 120
Follow-up: 24-month
Type of lesions: femoropopliteal arteries TASC A & B
Final results show that the iVolution stent is a valid and effective alternative to treat femoropopliteal TASC A&B lesions. The outstanding flexibility and the high-quality nitinol of the stent makes the difference.
These results confirm the already existing enthusiasm of the use of bare metal self-expandable nitinol stents in the treatment of TASC A&B femoropopliteal lesions. Longer follow-up and a comparison or addition with drug-eluting technology has to be studied in the future.
Dr. Marc Bosiers (São Paulo, Brazil)
All Clinical Trials